MiddleBrook Hires TalenTactics to Recruit National Field Force
October 22 2008 - 7:30AM
PR Newswire (US)
GERMANTOWN, Md., Oct. 22 /PRNewswire-FirstCall/ -- MiddleBrook
Pharmaceuticals, Inc. (NASDAQ:MBRK), a pharmaceutical company
focused on developing and commercializing novel anti-infective
products, today announced that it has retained pharmaceutical
recruiting firm TalenTactics LLC to lead its field force hiring
effort in preparation for the Company's MOXATAG(TM) (amoxicillin
extended-release tablets, 775mg) launch. The launch is targeted for
the first half of 2009. MiddleBrook President and CEO John Thievon
commented, "TalenTactics served as a valuable partner for three
Adams Respiratory Therapeutics sales force expansion projects, and
its recruiting expertise in the healthcare space will be an
invaluable asset to MiddleBrook. We plan to hire about 200 people
for our national field force, which will lead our effort to inform
healthcare practitioners about the important advantages of MOXATAG,
the first and only FDA-approved once-daily amoxicillin." "We are
proud and delighted that MiddleBrook Pharmaceuticals has chosen
TalenTactics to be their strategic partner in building this, their
initial national sales force," stated George W. Scott, president of
TalenTactics LLC. "MOXATAG and MiddleBrook's exciting pipeline
represent an excellent opportunity for the people we will recruit
into this sales force. We look forward to a mutually beneficial
business relationship for years to come," he added. Interested job
applicants can find more information about the Company's open
positions and apply online at the Careers section of MiddleBrook's
web site, http://www.middlebrookpharma.com/. ABOUT MOXATAG: MOXATAG
(extended-release amoxicillin) 775mg tablets are a once-a-day
extended-release formulation of amoxicillin for oral administration
consisting of three components: one immediate-release component and
two delayed-release components. The three components are combined
in a specific ratio to prolong the release of amoxicillin from
MOXATAG compared to immediate-release amoxicillin. MOXATAG is
intended to provide a lower treatment dose, once- daily alternative
to currently approved penicillin and amoxicillin regimens for the
treatment of adults and pediatric patients 12 years and older with
tonsillitis and/or pharyngitis. ABOUT MIDDLEBROOK PHARMACEUTICALS:
MiddleBrook Pharmaceuticals, Inc. (NASDAQ:MBRK) is a pharmaceutical
company focused on the development and commercialization of
anti-infective drug products that fulfill substantial unmet medical
needs in the treatment of infectious disease. The Company is
developing anti-infective drugs based on its novel biological
finding that bacteria exposed to antibiotics in pulses are killed
more efficiently than those under standard treatment regimens.
Based on this finding, MiddleBrook has developed a proprietary,
once-a-day pulsatile delivery technology called PULSYS(R). The
Company currently markets the KEFLEX(R) brand of cephalexin and has
received regulatory approval for MOXATAG(TM) -- the first and only
once-daily amoxicillin product approved for marketing in the U.S.
For more information about MiddleBrook, please visit
http://www.middlebrookpharma.com/. ABOUT TALENTACTICS LLC:
TalenTactics is a pharmaceutical/ bio-pharmaceutical recruiting
firm dedicated to the building, expansion, and maintenance of sales
forces in the industry. To date TalenTactics has built upwards of
40 sales forces, large and small, and has placed over 5,000 sales
and sales management professionals within the industry. Located in
Conshohocken, PA, TalenTactics recruits nationally for
pharmaceutical sales professionals and sales management talent from
entry level to vice president levels. This announcement contains
forward-looking statements, within the meaning of the Securities
Exchange Act of 1934 and the Securities Act of 1933, that involve
risks and uncertainties. In some cases, forward-looking statements
are identified by words such as "believe," "anticipate," "expect,"
"intend," "plan," "will," "may" and similar expressions. You should
not place undue reliance on these forward-looking statements, which
speak only as of the date of this announcement. All of these
forward-looking statements are based on information available to us
at this time, and we assume no obligation to update any of these
statements. Actual results could differ from those projected in
these forward-looking statements as a result of many factors,
including those identified in the sections titled "Risk Factors" in
our Registration Statement on Form S-3 as filed with the Securities
and Exchange Commission on October 17, 2008, and in our
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" and elsewhere in our Annual Report on Form
10-K for the year ended Dec. 31, 2007. We urge you to review and
consider the various disclosures made by us from time to time in
our filings with the Securities and Exchange Commission, that
attempt to advise you of the risks and factors that may affect our
future results. DATASOURCE: MiddleBrook Pharmaceuticals, Inc.
CONTACT: Faith Pomeroy-Ward, MiddleBrook Pharmaceuticals, Inc.,
+1-301-944-6585 Web site: http://www.middlebrookpharma.com/
Copyright
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Jul 2024 to Aug 2024
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Aug 2023 to Aug 2024